bioRxiv · 10.1101/2023.02.01.526731
Systematic Analysis of KRAS-ligand Interaction Modes and Flexibilities Reveals the Binding Characteristics
Abstract
KRAS, a common human oncogene, has been recognized as a critical drug target in treating multiple cancers. After four decades of effort, one allosteric KRAS drug (Sotorasib) has been approved, inspiring more KRAS-targeted drug research. Here we provide the features of KRAS binding pockets and ligand-binding characteristics of KRAS complexes using a structural systems pharmacology approach. Three distinct binding sites (conserved nucleotide-binding site, shallow Switch-I/II pocket, and allosteric Switch-II/3 pocket) are characterized. Ligand-binding features are determined based on encoded KRAS-inhibitor interaction fingerprints. Finally, the flexibility of the three distinct binding sites to accommodate different potential ligands, based on MD simulation, is discussed. Collectively, these findings are intended to facilitate rational KRAS drug design.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Zhao, Z., Bohidar, N., Bourne, P. E.. 2023-02-04. Systematic Analysis of KRAS-ligand Interaction Modes and Flexibilities Reveals the Binding Characteristics. https://doi.org/10.1101/2023.02.01.526731
Cite the original work for its findings. Save a collection to share your selection of sources.